What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Melanoma, Immunology, Oncology and Ipilimumab.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery.
His Melanoma research is multidisciplinary, incorporating elements of Mutation, Cancer, Skin cancer and CD8.
His studies deal with areas such as Keratinocyte, Histamine H4 receptor and Histamine as well as Immunology.
His study in Oncology is interdisciplinary in nature, drawing from both Binimetinib, Vemurafenib and Neuroblastoma RAS viral oncogene homolog.
His Ipilimumab research is multidisciplinary, incorporating perspectives in Immune checkpoint, Retrospective cohort study, Cutaneous melanoma and Adjuvant therapy.
His most cited work include:
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2107 citations)
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. (1377 citations)
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (659 citations)
What are the main themes of his work throughout his whole career to date?
Ralf Gutzmer spends much of his time researching Internal medicine, Melanoma, Oncology, Immunology and Histamine.
Ralf Gutzmer interconnects Gastroenterology and Surgery in the investigation of issues within Internal medicine.
His study in Melanoma focuses on Binimetinib in particular.
His research investigates the link between Oncology and topics such as Vemurafenib that cross with problems in Dermatology.
His Histamine study integrates concerns from other disciplines, such as Histamine receptor, Receptor and Histamine H4 receptor, Histamine H2 receptor.
Pembrolizumab is closely connected to Nivolumab in his research, which is encompassed under the umbrella topic of Ipilimumab.
He most often published in these fields:
- Internal medicine (50.31%)
- Melanoma (38.75%)
- Oncology (34.69%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (50.31%)
- Oncology (34.69%)
- Melanoma (38.75%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Melanoma, In patient and Adverse effect.
His Internal medicine course of study focuses on Placebo and Adjuvant therapy and Hazard ratio.
His study on Oncology also encompasses disciplines like
- Systemic therapy most often made with reference to Immunotherapy,
- Clinical trial and related Randomized controlled trial.
His Melanoma study combines topics in areas such as Immune checkpoint, Cancer, Targeted therapy, Skin cancer and V600E.
His research in Adverse effect intersects with topics in Basal cell carcinoma, Toxicity and Standard treatment.
His work in Ipilimumab tackles topics such as Myositis which are related to areas like Myasthenia gravis.
Between 2018 and 2021, his most popular works were:
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial (78 citations)
- Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. (69 citations)
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. (39 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Ralf Gutzmer mainly investigates Internal medicine, Oncology, Adverse effect, Melanoma and Nivolumab.
His study looks at the intersection of Internal medicine and topics like Placebo with Adjuvant therapy and Cancer.
His Oncology research is multidisciplinary, relying on both Tolerability, MEK inhibitor, Radiation therapy and Phases of clinical research.
In his research, Standard treatment, Discontinuation and Trametinib is intimately related to Vemurafenib, which falls under the overarching field of MEK inhibitor.
His Melanoma study incorporates themes from V600E and Targeted therapy.
His Nivolumab research incorporates elements of Ipilimumab and Myositis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
